Related Experiment Video
Updated: Apr 14, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Targeting the hyaluronic acid-CD44 axis in hepatocellular carcinoma
Georgia Zancotti1, Gisela Weiz2, Cyrollah Disoma1
1Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Basovizza, Trieste 34049, Italy; Doctoral School of Molecular Biomedicine, Department of Life Sciences, University of Trieste, Trieste 34149, Italy.
Targeting the hyaluronic acid (HA) and cluster of differentiation 44 (CD44) interaction can overcome drug resistance in hepatocellular carcinoma (HCC). This strategy offers a promising avenue for developing personalized HCC treatments and improving patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) presents significant global health challenges due to increasing incidence and limited treatment efficacy.
- Drug resistance and poor long-term survival persist in HCC despite advancements in systemic therapies.
- The tumor microenvironment, specifically the interaction between hyaluronic acid (HA) and cluster of differentiation 44 (CD44), is implicated in HCC progression and therapeutic failure.
Purpose of the Study:
- To review and highlight strategies targeting the HA-CD44 signaling axis in hepatocellular carcinoma.
- To explore potential therapeutic approaches for overcoming drug resistance in HCC by modulating HA-CD44 interactions.
- To discuss the role of HA-CD44 biology in personalized treatment development for HCC.
Main Methods:
- Review of current literature on HA-CD44 signaling in HCC.
- Analysis of therapeutic strategies targeting HA synthesis, degradation, and CD44 blockade.
- Evaluation of HA-based nanocarriers for targeted drug delivery in HCC treatment.
Main Results:
- The HA-CD44 axis is a critical factor in HCC tumor progression and resistance to therapy.
- Targeting HA-CD44 interactions presents a promising strategy to enhance treatment efficacy.
- Various approaches, including drug delivery systems, show potential for overcoming resistance.
Conclusions:
- Modulating the HA-CD44 signaling pathway offers a promising therapeutic strategy for hepatocellular carcinoma.
- Personalized treatment approaches leveraging HA-CD44 biology can improve patient outcomes.
- Further research into HA-CD44 targeted therapies is warranted to enhance HCC management.
